Tu Youyou was born in Ningbo in 1930, her name drawn from the Book of Songs. After graduating from Peking University Medical School's pharmacy department in 1955, she was assigned to the Academy of Chinese Medicine — and stayed there her whole life. In 1967, with the Vietnam War raging and a chloroquine-resistant strain of malaria devastating the jungle battlefields, China launched the top-secret military "Project 523" to find a new antimalarial. In 1969, the 39-year-old Tu was named group leader. She combed through more than two thousand old recipes and screened over three hundred herbs; in 1971, inspired by a line in Ge Hong's Handbook of Prescriptions for Emergencies (4th c.), she used low-temperature ether to extract a sweet-wormwood compound that inhibited the malaria parasite 100%, then isolated the pure molecule, artemisinin — which has since saved millions of lives. She won the Lasker Award in 2011 and, in 2015, became the first China-based scientist to win a Nobel in a science category.
January 1969: bet everything on classical Chinese medicine. Project 523 had already screened tens of thousands of synthetic compounds with almost nothing to show. Tu faced two roads: keep synthesizing new molecules with the main force, or go back into the dusty medical classics. She chose the latter — spending three months compiling a handbook of 640-plus antimalarial folk recipes and testing them one by one. It looked like a backward "peasant method," but it shrank an astronomical search space down to candidates already filtered by millennia of clinical experience.
1971: overturn her own extraction method for one sentence by Ge Hong. The water decoction of sweet wormwood worked erratically; the team nearly gave up on it. Re-reading Ge Hong's Handbook, Tu paused on the malaria remedy: "A handful of qinghao, soaked in two litres of water, wring out the juice, and drink it all" — not boiled, but pressed raw. She suddenly saw it: heat may be destroying the active ingredient. She switched to ether, which boils at just 35°C, extracting at low temperature. On October 4, 1971, sample No. 191 — the neutral ether extract — hit 100% inhibition against malaria in mice and monkeys for the first time. One old sentence turned the whole direction.
Sources: Tu Youyou, Artemisinin and Artemisinin-Based Drugs (2009); Rao Yi et al., "A Milestone in Chinese Materia Medica Research" (2011); Nobel Lecture (2015).Sample No. 191 worked in animals, but before any human trial it had to be proven safe for people. It was the Cultural Revolution; there was no orderly clinical-approval process, and a few officials, worried about toxicity, had the trial stuck.
In July 1972 Tu filed a request with leadership: "I am the group leader; it is my responsibility to test the drug first." She and two colleagues checked into Dongzhimen Hospital in Beijing as the first human subjects for the artemisinin extract — testing the poison on their own bodies. A week of observation showed no serious side effects, and only then could human trials proceed. That autumn the team rushed to malaria districts on Hainan Island and ran clinical tests with striking results. That act of "making myself the lab rat" turned a lab number into a drug that saved real patients — and later became the hardest ground on which she stood when the Nobel was awarded to her alone.
Sources: Nobel Lecture (2015); Tu's own account and People's Daily interview (2015).To throw herself into the work, she sent both daughters away. When she took over 523, her husband had been sent to a labor camp; she placed her not-yet-four-year-old elder daughter in a full-time boarding nursery and sent the infant younger one back to grandparents in Ningbo. Years later the younger girl, returning to Beijing, briefly failed to recognize her own mother. It was the deepest debt of Tu's life.
She did the extractions in an unventilated shack — and it made her sick. The lab was primitive and unprotected; ether and other solvents were distilled in big open vats. Chronic inhalation of the fumes gave her toxic hepatitis and damaged her eyesight — to cure others' disease, she first caught her own.
She was silent, stubborn, and awkward with people. Colleagues recall she "couldn't dance and didn't much like being photographed," and in interviews she could never produce a polished sound bite — only talk, again, about experiments and data. That lack of smoothness kept her focused, and later cost her repeatedly in awards.
After fame, her habits held. Even after the Nobel she kept living in her old work-unit building, donated most of the prize money to set up training funds at Peking University Medical School and the Academy of Chinese Medicine. What she wanted was never the pomp, but to keep the artemisinin work going.
Sources: People's Daily and China Newsweek interviews (2015); public reporting after the award.First, "who deserves first credit" has been argued for decades. Project 523 was a nationwide campaign — 60-plus institutions and 500-plus researchers took part, and teams in Yunnan and Shandong contributed heavily to purification and structure determination. Tu was the crucial "igniter" — first to get 100% inhibition via ether extraction, first to isolate the pure molecule — but crediting the whole enterprise to one person drew open protest from some of the era's participants. The Nobel's "lone hero" frame sits in permanent tension with the collective history.
Second, the "three-noes scientist" mismatch. Tu holds no doctorate, no overseas study, and was never elected to the Chinese Academy of Sciences or Engineering. That someone doing Nobel-grade work repeatedly failed academician elections exposes a deep gap between institutional metrics (titles, papers, seniority) and real contribution — though some note her tough personality and poor people skills sharpened the dispute.
Third, delayed publication and tangled authorship. Because of secrecy and the Cultural Revolution, artemisinin could not be published under any individual's name for years. The first 1977 paper was signed collectively as the "Qinghaosu Structure Research Collaboration Group," with no individual credited — forced by the times, but making later priority claims nearly impossible and seeding decades of dispute.
Sources: Li Runhong, Rao Yi & Zhang Daqing, The Discovery of Artemisinin (2017); Miller & Su, Cell (2011) on the history of artemisinin.Tu's lesson for the "AI super-individual" lies in how she shrank the search space. While the main force brute-forced tens of thousands of compounds, she turned back to the classical pharmacopeia — a "prior" distilled from millennia of human clinical experience, effectively pruning an astronomically large search space. That is the core posture of solving hard problems with AI today: rather than brute-force search, first find a high-quality prior to constrain the direction. Subtler still was the "re-read an old text, change the method" move — real breakthroughs often come from taking one overlooked old clue and re-reading it inside today's problem. But her shadow is also a warning: the lone-hero narrative flattens the whole system that lifts you up. Two things to take from her — the wisdom of pruning search with priors, and the plodding grit to sit the coldest bench and test it on yourself.